phase readout

NCT04439266: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

ACTIVE_NOT_RECRUITINGupdated 13h ago

community read0 votes

Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma

view source ↗

NCT04439266: Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Report a data issue

comments(0)